3158-73-4Relevant articles and documents
Bcl-2 INHIBITORS
-
Paragraph 0806; 0807, (2019/11/19)
Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.
SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS
-
Page/Page column 42, (2013/10/22)
The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.
Aminopyrroline compounds
-
, (2008/06/13)
Compound of formula (I): in which: n is 1 or 2, X represents alkylene, alkenylene, alkynylene or optionally substituted arylene or heteroarylene, R10represents hydrogen or alkyl and R11and R12together form a bond, or alternatively R12represents hydrogen or alkyl and R10and R11together form a bond, R2, R3and R4each independently of the others represents hydrogen, alkyl, hydroxyalkyl, alkoxy, alkoxycarbonyl, aryl, arylalkyl or aryloxyalkyl, or two of R2, R3and R4form a cycloalkyl radical. Medicinal products containing the same are useful in the treatment of cardiovascular diseases.